Physician profile
Miranda Gardner
NPI 1114406568
$1,079.65
in general payments reported to CMS, 2019-2025
15 companies · $20.73 in 2025
The $20.73 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $132 · 2022: $483 · 2023: $329 · 2024: $116 · 2025: $20.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $462.50 | 2021-2025 | |
| Glaxosmithkline, LLC. | $104.78 | 2021-2024 | Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $84.37 | 2022-2024 | Mounjaro, Zepbound |
| Novo Nordisk INC | $83.75 | 2021-2024 | Ozempic, Rybelsus |
| Neurocrine Biosciences, INC. | $73.71 | 2022-2023 | Ingrezza |
| Takeda Pharmaceuticals U.S.A., INC. | $50.58 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $49.81 | 2022 | |
| Pfizer INC. | $35.70 | 2024 | |
| Ironshore Pharmaceuticals INC. | $33.47 | 2022-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $29.59 | 2022-2023 | Qelbree |
| Axsome Therapeutics, INC. | $17.00 | 2024 | Auvelity |
| Biohaven Pharmaceutical Holding Company Ltd. | $15.19 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.97 | 2023 | Austedo |
| Exact Sciences Corporation | $13.33 | 2023 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Miranda Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.